中韩卒中血脂专家论坛-有关最新降脂治疗现状 & TST研究

医脉通 2022.09.07

安进·安e学

11条内容

参考文献：

1.Mach F, Baigent C, Catapano A L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Atherosclerosis, 2019, 290: 140-205. DOI: 10.1093/eurheartj/ehz455

2.Kleindorfer D O, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association[J]. Stroke, 2021, 52(7): e364-e467. DOI: 10.1161/STR.0000000000000375.

3.Amarenco P, Kim J S, Labreuche J, et al. A comparison of two LDL cholesterol targets after ischemic stroke[J]. New England Journal of Medicine, 2020, 382(1): 9-19. DOI: 10.1056/NEJMoa1910355.

4.Lau K K, Chua B J, Ng A, et al. Low‐Density Lipoprotein Cholesterol and Risk of Recurrent Vascular Events in Chinese Patients With Ischemic Stroke With and Without Significant Atherosclerosis[J]. Journal of the American Heart Association, 2021, 10(16): e021855. DOI:10.1161/JAHA.121.021855.

5.Amarenco, P, Benavente, O, Goldstein, LB, Callahan, A, Sillesen, H, Hennerici, MG, Gilbert, S, Rudolph, AE, Simunovic, L, Zivin, JA, Welch, KMA: Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke, 40: 1405-1409, 2009. DOI: 10.1161/STROKEAHA.108.534107.

6.Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials[J]. Lancet (London, England), 2010, 376(9753): 1670-1681. DOI: 10.1016/s0140-6736(10)61350-5.

7.Amarenco P, Kim J S, Labreuche J, et al. Intracranial hemorrhage in the TST trial[J]. Stroke, 2022, 53(2): 457-462. DOI:10.1161/STROKEAHA.121.035846.

8.Goldstein L B, Amarenco P, Szarek M, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study[J]. Neurology, 2008, 70(24 Part 2): 2364-2370. DOI: 10.1212/01.wnl.0000296277.63350.77.

9.Benn M, Nordestgaard B G, Frikke-Schmidt R, et al. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study[J]. bmj, 2017, 357. DOI: 10.1136/bmj.j1648

10.Giugliano R P, Pedersen T R, Park J G, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial[J]. The Lancet, 2017, 390(10106): 1962-1971. DOI: 10.1016/S0140-6736(17)32290-0.